Stephanie S Yee

10PUBLICATIONS
33CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer diagnosisGene expression (incl. microarray and other genome-wide approaches)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Vivek Narayan, Julie S Barber-Rotenberg, In-Young Jung

|Jun 07, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.

Jeffrey C Thompson, Erica L Carpenter, Benjamin A Silva

|Oct 17, 2020
THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.

Shirsa Udgata, Naomi Takenaka, William R Bamlet

|Oct 03, 2020
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.

Naomi B Haas, Michael J LaRiviere, Thomas H Buckingham

|Apr 18, 2020
A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.

Zijian Yang, Michael J LaRiviere, Jina Ko

|Feb 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Charu Aggarwal, Jeffrey C Thompson, Austin L Chien

Pageof 2

Frequent Collaborators

2 joint publications

Jacob E Till

2 joint publications

Michael J LaRiviere

2 joint publications

Joshua M Bauml

2 joint publications

Erica L Carpenter